Mark C. Wiggins - 28 Jan 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.

Reporting relationship: Chief Business Officer
Issuer ticker: N/A
Reported as of: 28 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Feb 2022, 16:00:31 UTC
Prior SEC filing: 28 May 2021
Next SEC filing: 09 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Scott B. Brown, Attorney-in-Fact

Key filing fact

Mark C. Wiggins filed Form 4 for Tracon Pharmaceuticals, Inc. on 01 Feb 2022.

Key facts

This page summarizes Mark C. Wiggins's Form 4 filing for Tracon Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Feb 2022, 16:00.

Change

Previous filing in this sequence was filed on 28 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TCON transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +80,000
Change %
Price: $0.000000
Shares after: 80,000
Date: 28 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $2.32
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/4th of the shares subject to this option shall vest on the first anniversary of the Grant Date shown in column 3 above. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter, on the last day of each month.